🚗 🚙 Turn your trusty old car into trustworthy journalism Learn more

Investors pressure Moderna to broaden global access to vaccine

Dec 28, 2021
The company is under scrutiny over vaccine equity. It received considerable U.S. government help in developing its vaccine.
As the omicron variant spreads, some shareholders of Moderna are criticizing the company, arguing its price for the COVID-19 vaccine is too high for low-income countries.
Angela Weiss/AFP via Getty Images